Regulatory Risk and Business Development: Type 2 Diabetes Falls Out of Favor

Article preview from "The RPM Report" October 28, 2008

If you think this is a bad time to try to get a loan, try selling a type 2 diabetes research project to a Big Pharma company...

Article preview from "The RPM Report" October 28, 2008

Regulatory Risk and Business Development: Type 2 Diabetes Falls Out of Favor

If you think this is a bad time to try to get a loan, try selling a type 2 diabetes research project to a Big Pharma company.

Diabetes, simultaneously one of the largest yet most under-treated prescription drug markets in the world, is suddenly out-of-favor with Big Pharma business development executives. And the reason isn’t hard to spot: the belief that regulatory hurdles have fundamentally changed the business case for drug development in the category.

Here is what executives from a few companies have to say:

You can read the rest of this article and many more like it, by purchasing a membership to The RPM Report today.

Companies mentioned in this article
Eli Lilly
Merck
Wyeth
Genzyme
Pfizer
Novo Nordisk